Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
SYS-CON.TV
Today's Top SOA Links


OriGene Publishes Landmark Paper on Revolutionary Proteome Platform for Antibody Specificity Test
Key Publication Further Validates OriGene's Unique Approach and Application of Protein Microarray Technology to Analyze Antibody Specificity

ROCKVILLE, Md., Jan. 7, 2013 /PRNewswire/ -- OriGene Technologies, Inc. ("OriGene"), one of the industry leaders in producing genome wide products for research and diagnostic applications, has brought the antibody field one step closer to identifying and developing ultra-specific monoclonal antibodies.  Specificity of antibodies for research or clinical applications is of critical importance and therefore it is a "must" to demonstrate antibody specificity with high confidence.  Leveraging more than ten years of product development expertise, OriGene has generated a breakthrough mammalian-cell expressed antigen chip which contains greater than 50% of the human proteome ("Protein Microarray Technology").  OriGene's Protein Microarray Technology key utility is to verify diagnostic and therapeutic antibody specificity and identify cross-reactivity.  Antibody cross-reactivity is a major cause of concern throughout the industry with the development and commercialization of diagnostic and therapeutic antibodies. 

(Logo: http://photos.prnewswire.com/prnh/20130107/DC38100LOGO)

As published in BMC Biotechnology 2012, 12:88, OriGene's Protein Microarray Technology chip was successfully used to evaluate the specificity of the commonly used anti-ERCC1 antibody called 8F1.  This ERCC1 antibody is being explored as a predictive diagnostic biomarker for cisplatin-based chemotherapy.  OriGene was able to utilize its proprietary technology to determine that the 8F1 antibody cross-reacts with a previously unknown nuclear protein called PCYT1A and thus is not suitable for use in IHC assays for ERCC1 detection. (view Abstract)

"This result is important, as it could explain some of the inconsistencies seen in comparative studies done on the 8F1 antibody. Using antibodies which cross-react with a nuclear protein PCYT1A when testing for ERCC1 may potentially lead to an incorrect IHC test result," says Wei-Wu He, Ph.D., who is CEO of OriGene and one of the co-authors of the scientific study.

OriGene utilized its Protein Microarray Technology to screen 18 monoclonal antibodies to identify two unique UltraMAB™ antibody clones, 4F9 and 2E12, and confirmed that these are truly "mono-specific." Every UltraMAB™ antibody is validated for IHC and for immunoassay analysis, and verified to have non-specific cross-reactivity by utilizing OriGene's Protein Microarray Technology. Consequently, each UltraMAB™ is specificity verified to an unprecedented level, ensuring superior performance for IHC applications.  In 2012, OriGene generated over 20 UltraMAB™ antibodies and its future plans are to launch new UltraMAB™ antibodies on a regular basis. 

Detailed information about the Protein Microarray Technology and a complete listing of the UltraMAB™ antibody product line is available at www.origene.com/UltraMAB, where customers can learn more about OriGene's unique approach to ultra-specific monoclonal antibody development.  

About OriGene
OriGene Technologies, Inc. develops, manufactures, and sells genome wide research and diagnostic products worldwide.  OriGene's research business offers one of the world's largest collections of cDNA clones, human proteins, antibodies and assays for use to study gene functions.  Leveraging the recent advances in the human genome, OriGene utilizes its innovative R&D in the U.S. and large scale capacity in China to produce an extensive array of ultra-specific monoclonal antibodies called UltraMAB™ which offers significantly value added diagnostic benefits for disease screening and personalized medicine treatment. OriGene's Protein Microarray Technology is used for QC diagnostic and therapeutic specificity and other protein-protein interactions.   For more information, visit www.OriGene.com.

SOURCE OriGene Technologies, Inc.

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Web 2.0 Latest News
With Octoblu emerging from stealth mode, it seemed like a good idea to talk to a couple of key people there. We were able to do just that with company co-founders Geir Ramleth and Chris Matthieu. Geir Ramleth serves as CEO. He was named to CIO Magazine's Hall of Fame in 2008, and ser...
Like most maturing industries, standards are required to achieve broad adoption and maximum value. For the cloud, in particular cloud Infrastructure as a Service (IaaS) offerings like Amazon Web Services and Rackspace Cloud, it’s time for a standard method for presenting these services...
If you listen to the persistent murmur in the market surrounding the Internet of Things right now, you'd believe that it's all about sensors. Sensors and big data. Sensors that monitor everything from entertainment habits to health status to more mundane environmental data about your h...
Open Source Storage recently announced that Oracle veteran Mark Iwanowski was joining the company as its new chairman. What better time to find out what's going on there? We had a few questions for him... Cloud Computing Journal: What are your key objectives as the new Chairman? ...
The IoT is coming, as inevitably as the earth circles the sun. It's just a matter of how many laps the planet will take before we have an IoT society characterized by smart things, buildings, grids, cities, and nations. One question to ponder is which of those nations are best equip...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021




SYS-CON Featured Whitepapers
ADS BY GOOGLE